Kuntz, MD, was a fellow about 45 years ago, there were few more devastating diagnoses than Duchenne muscular dystrophy (DMD).

Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...

Opens in a new tab or window SAVANNAH, Ga. -- Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, missed its primary endpoint but differences ...

People hit the road for a short race Saturday to support research into Duchenne muscular dystrophy. The GR .1K was held ...

Duchenne, has been a transformative force in the fight against Duchenne muscular dystrophy (DMD). Following her son Hawken’s ...

We have commenced the submission of our BLA which we expect to be complete by year end and we have significantly strengthened our balance sheet in order to scale ... development for the treatment of ...

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is ...

PTC Therapeutics' NDA resubmission of Translarna was based on data from Study 041 and the long-term STRIDE registry. No PDUFA action date was provided for regulators.

When Mats died of a terminal disease, messages flooded to his parents from the community of gamers with whom he had an unknown, vibrant life. Good luck keeping your eyes dry.

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Wave Life Sciences (NASDAQ:WVE) stands against other biggest ...

Zinc supplementation showed limited benefits in improving muscle health and hydration in boys with DMD. Nearly 30% of participants had low zinc levels initially, with slight improvement post ...